{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-073084","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.204991+00:00","generated_at":"2026-06-25T00:03:50.025235+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"HOOKIPA CMO resigns; Schlienger and Necina promoted effective July 1","bullets":["CMO Igor Matushansky resigns effective June 30, 2022; will chair Scientific Advisory Board.","Katia Schlienger promoted to EVP Clinical Development, joins Executive Team.","Roman Necina appointed Chief Development Officer, integrating manufacturing and project management.","Gilead registration rights agreement filed; Gilead may purchase up to $35M in common stock; initial $5M at $3.00/share."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-073084","json":"https://secwatch.observer/filing/0001104659-22-073084.json","markdown":"https://secwatch.observer/filing/0001104659-22-073084.md","text":"https://secwatch.observer/filing/0001104659-22-073084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/0001104659-22-073084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/tm2218404d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:03:50.025235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c7004f3a4","claim":"Igor Matushansky was appointed as Chair of Scientific Advisory Committee at HOOKIPA Pharma Inc..","evidence_excerpt":"Dr. Matushansky was also appointed to chair the Company’s newly formed Scientific Advisory Committee.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/0001104659-22-073084-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of Scientific Advisory Committee"}],"fact_type":"executive_change"},{"claim_id":"acdfe73778","claim":"Igor Matushansky resigned as Chief Medical Officer and Global Head of Research and Development at HOOKIPA Pharma Inc..","evidence_excerpt":"On June 20, 2022, Igor Matushansky, M.D., Ph.D., who has served as the Chief Medical Officer and Global Head of Research and Development of the Company, notified the Company that he will resign from his current positions, effective as of June 30, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/0001104659-22-073084-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer and Global Head of Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}